Compare Abbott Laboratories (ABT) vs American Water Works Company Inc (AWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs American Water Works Company Inc — how do they compare? Abbott Laboratories trades at $95.43 (market cap $166.94B), while American Water Works Company Inc trades at $133.97 (market cap $26.33B). The key difference: Abbott Laboratories is far larger — about 6.3× American Water Works Company Inc's market cap, and American Water Works Company Inc pays the higher dividend (2.66%). Which is the better fit depends on your goals.
| ABT | AWK | |
|---|---|---|
Market Cap | $166.94B | $26.33B |
Sector | Health | Utilities |
52-Week High | $136.62 | $147.00 |
52-Week Low | $82.57 | $121.13 |
Enterprise Value | $193.69B | $41.89B |
Dividend Yield | 2.63% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
AWK trades at $134.82, down 1.49% today, near the consensus price target of $134.50. The stock shows a bullish technical trend with strong moving averages, while recent earnings have been mixed with two misses in the last three quarters. Revenue grew to $5.14B in 2025, with a net income margin of 21.17%, and the company continues strategic acquisitions and infrastructure investments, as seen in recent news (PRNewsWire, June 30, 2026).
Outlook remains stable with analyst consensus leaning buy (46.66% buy ratings), but risks include high debt levels and regulatory pressures. The stock offers steady growth potential through capital investments, though margin pressures and interest expenses could limit upside. Investors should weigh the defensive utility sector appeal against valuation multiples like a P/E of 23.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →
